32
“Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo – Brazil

“Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

“Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo – Brazil

Page 2: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Hemoglobin Molecule 4 polypeptide chains and 4 heme groups

Page 3: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Normal hemoglobin

• 2 cadeias a e 2 cadeias b ® HbA

• 2 cadeias a e 2 cadeias d ® HbA2

• 2 cadeias a e 2 cadeias g ® HbF

• vida fetal predomina HbF

• padrão adulto em torno de 1 ano

Page 4: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Definition

1. Heterogeneous group of hereditary diseases

2. Decrease or absence of synthesis of 1 or more

Globin chains of the hemoglobin molecule

Page 5: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

1925 - Thomas Cooley e Peter Lee Severe anemia, splenomegaly and bone abnormalities Characteristics in children of Mediterranean origin Talassemia - thalassa = mar

1940 - Genetic disease, Mendelian, widely distributed

50 - Heterogeneous disease, at least 2 types: a and b

60 e 70 - Methods for studying globin synthesis in vitro

Subsequent years - molecular biology techniques Definition of the molecular pathology of the various forms of Thalassemia

Historic

Page 6: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Incidence in Brazil

Page 7: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Prevalence and Geographical Distribution

3% of the world 's population = carrier of 1 b - tal gene

Ferrara: 20% Sardinia: 11 to 34% Sicily: 10% Greece: 5 to 15%

Lowest frequency: Africa, Turkey, Iran Sporadic: Northern Europe

USA and Brazil: descendants of Italians, Greeks and Blacks

Page 8: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Pathophysiology Normal

Synthesis of 1 alpha chain: 1 non-alpha chain

Thalassemia

Deficiency of synthesis of 1 or + globin chains

Decreased hemoglobin synthesis hypochromia

Unbalance between the production of a and non-a chains disastrous consequences

Page 9: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Representation of the genomic structure of the α- and β-globin loci.

Stefano Rivella Haematologica 2015;100:418-430 ©2015 by Ferrata Storti Foundation

Page 10: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Rund D & Rachmilewitz E – N Engl J Med 2005; 353:1135-46

The excess of alpha globin causes the formation of Inclusion bodies (Heinz bodies) with lysis

Of intramedullary erythrocyte cells (Ineffective erythropoiesis)

Pathophysiology

Page 11: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Representation of some of the pathways regulating steady state and stress erythropoiesis and their relationship to ineffective

erythropoiesis in β-thalassemia.

Stefano Rivella Haematologica 2015;100:418-430 ©2015 by Ferrata Storti Foundation

Page 12: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Olivieri NF - New Engl Med 1999; 341: 99-109

Page 13: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Illustration of the relationship between anemia, hypoxia, Epo, erythropoiesis and iron metabolism in β-tha-lassemia.

Stefano Rivella Haematologica 2015;100:418-430

Page 14: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Cunningham MJ et al. Blood 2004;104:34–39

0

10

20

30

40

50

60

70

80

0–15 years 16–24 years >25 years

Cardiac

Cirrhosis Endocrine

Num

ber o

f tha

lass

emia

com

plic

atio

ns

Complications

Page 15: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Talassemia Intermédia Hematopoese Extramedular

Page 16: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Talassemia Major

Page 17: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Cunningham MJ et al. Blood 2004;104:34–39

0

10

20

30

40

50

60

70

80

0–15 years 16–24 years >25 years

Cardiac

Cirrhosis Endocrine

Num

ber o

f tha

lass

emia

com

plic

atio

ns

Complicações

Page 18: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Treatment

} Hematopoietic stem cell transplantation } Blood Transfusion } Iron Chelation } Splenectomy } hidroxiuréia } Eritropoetina

} Gene Terapy

1. Lawson SE et al. Br J Haematol 2003;120:289–295; 2. Li CK et al. Pediatr Hematol Oncol 2004;21:411–419; 3. Cohen A et al. Am J Hematol 1989;30:254–256; 4. Arruda VR et al. N Engl J Med 1997;336:964–965; 5. Chaidos A et al. Acta Haematol 2004;111:189–195; 6. Puthenveetil G & Malik P. Curr Hematol Rep 2004;3:298–305

Page 19: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Potential use of JAK2 inhbitors in β-thalassemia.

Stefano Rivella Haematologica 2015;100:418-430

Page 20: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Iron Overload • Increased intestinal absorption

• Repeated transfusion of red blood cells

1 Red cell concentrate unit 200 mg iron

Iron concentration transfusion dependet patient = 0,4 a 0,5 mg Fe/Kg/dia

Page 21: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Iron overload Free Iron

NTBI

Stress oxidativo

Lipid peroxidation

Injury of organelles Lysosomes, mitochondria

TGF b

Collagen Synthesis Lysosomal Fragility Enzyme leakage

cell death Fibrosys

Page 22: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Liver: Coloração de Perls

Necrópsia Paciente MF

Page 23: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

RNM hepática

The top four images were collected from a patient having a liver iron of 6 mg/g. The bottom four images were collected from a normal volunteer. All images darken as the echo time (TE) lengthens, but the iron-heavy tissue darkens faster. The half life of this process is called T2* and the rate is called R2* (R2*=1000/T2*)

Page 24: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

R2* x Conc iron of liver biopsy

Wood JC et al. Blood 2005; 106:1460-1465

R=0,97

Page 25: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

T2* Normal Deposição de Fe em b-tal

RNM cardíaca T2*

Page 26: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Wood JC. Curr Opin Hematol 2007; 14: 183-190

Page 27: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Pesaro’s Criteria

1. Hepatomegaly 2. Hepatic fibrosis 3. Iron chelation

OS

´I – 87% ´II- 85% ´III-80%

Bone Marrow Transplantation

Gaziev J e col, Bone Marrow Transplant. 2008; 42: S41

Page 28: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

BMT

Page 29: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo
Page 30: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo
Page 31: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

1. Iron chelation does not seem to be so fundamental 2. Adults can be transplanted! 3. Do not predict risk in adults! 4. There is no acute and chronic GVHD difference 5. There is a difference in mortality

Page 32: “Thalassemia: Pathophisiology and treatment update” · “Thalassemia: Pathophisiology and treatment update” Dr. Ricardo Helman Hospital Israelita Albert Einstein São Paulo

Obrigado! [email protected]